Abbvie-话题@MedSci - 梅斯（MedSci）

#Abbvie#

25篇内容 | 1637人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1479603, encodeId=599214e9603cb, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, objectType=article, longId=300761, objectId=3b82300e6134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b82300e6134, replyNumber=0, likeNumber=79, createdTime=2022-03-16, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b82300e6134, moduleTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b82300e6134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479602, encodeId=403314e9602bd, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=老花眼有救了？AbbVie提交新药上市申请, objectType=article, longId=207662, objectId=8b2320e66294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b2320e66294, replyNumber=0, likeNumber=86, createdTime=2021-02-28, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b2320e66294, moduleTitle=老花眼有救了？AbbVie提交新药上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8b2320e66294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479601, encodeId=d0ef14e9601a3, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=43, createdTime=2020-06-10, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479600, encodeId=cb1a14e96009f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, objectType=article, longId=195324, objectId=869819532415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869819532415, replyNumber=0, likeNumber=56, createdTime=2020-06-06, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869819532415, moduleTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=869819532415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479599, encodeId=d0e114e959974, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=45, createdTime=2020-02-04, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479598, encodeId=024414e95980c, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=60, createdTime=2019-12-09, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479597, encodeId=47a114e9597f9, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周, objectType=article, longId=180135, objectId=23d51801355a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23d51801355a, replyNumber=0, likeNumber=66, createdTime=2019-09-29, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23d51801355a, moduleTitle=FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=23d51801355a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479596, encodeId=f6fd14e9596d4, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=AbbVie靶向癌症干细胞的ADC药物Rova-T治疗小细胞肺癌失败，宣布终止研发计划, objectType=article, longId=178544, objectId=d3591e85445f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3591e85445f, replyNumber=0, likeNumber=69, createdTime=2019-09-03, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3591e85445f, moduleTitle=AbbVie靶向癌症干细胞的ADC药物Rova-T治疗小细胞肺癌失败，宣布终止研发计划, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d3591e85445f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例, objectType=article, longId=178359, objectId=35221e8359a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35221e8359a2, replyNumber=0, likeNumber=56, createdTime=2019-08-31, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35221e8359a2, moduleTitle=FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=35221e8359a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479594, encodeId=060a14e959478, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=AbbVie收购Mavupharma，以抓住肿瘤免疫新靶点STING的机遇, objectType=article, longId=175615, objectId=cfd91e561593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd91e561593, replyNumber=0, likeNumber=65, createdTime=2019-07-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd91e561593, moduleTitle=AbbVie收购Mavupharma，以抓住肿瘤免疫新靶点STING的机遇, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cfd91e561593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479593, encodeId=d35f14e959308, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据, objectType=article, longId=167754, objectId=98e616e75482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98e616e75482, replyNumber=0, likeNumber=49, createdTime=2019-06-07, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98e616e75482, moduleTitle=2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=98e616e75482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479592, encodeId=1a4d14e9592f6, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, objectType=article, longId=167491, objectId=1e2a16e491c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2a16e491c8, replyNumber=0, likeNumber=74, createdTime=2019-06-03, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2a16e491c8, moduleTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e2a16e491c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479591, encodeId=36ec14e95917a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=欧洲批准AbbVie的白细胞介素23单抗Skyrizi治疗银屑病, objectType=article, longId=165295, objectId=f4ee16529528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ee16529528, replyNumber=0, likeNumber=58, createdTime=2019-05-03, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ee16529528, moduleTitle=欧洲批准AbbVie的白细胞介素23单抗Skyrizi治疗银屑病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f4ee16529528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479590, encodeId=70f214e9590bb, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=即使高管薪酬审查很严厉，AbbVie首席执行官仍拿着2100万美元的巨额奖金, objectType=article, longId=162215, objectId=6a4216221574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a4216221574, replyNumber=0, likeNumber=78, createdTime=2019-03-14, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a4216221574, moduleTitle=即使高管薪酬审查很严厉，AbbVie首席执行官仍拿着2100万美元的巨额奖金, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6a4216221574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=70, createdTime=2019-03-03, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479588, encodeId=746814e95887f, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, objectType=article, longId=159211, objectId=6a41159211ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a41159211ca, replyNumber=0, likeNumber=58, createdTime=2019-01-31, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a41159211ca, moduleTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6a41159211ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479587, encodeId=2ca614e9587ff, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, objectType=article, longId=159161, objectId=a1f815916100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f815916100, replyNumber=0, likeNumber=67, createdTime=2019-01-31, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f815916100, moduleTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a1f815916100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479586, encodeId=0b9b14e958633, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, objectType=article, longId=156675, objectId=905a1566e5bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=905a1566e5bb, replyNumber=0, likeNumber=71, createdTime=2018-12-27, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=905a1566e5bb, moduleTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=905a1566e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479585, encodeId=fd9e14e9585de, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=49, createdTime=2018-09-28, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479584, encodeId=7dcd14e9584d5, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, objectTitle=EMA确认AbbVie的MS药物Zinbryta的风险超过益处, objectType=article, longId=138663, objectId=4ce31386639e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ce31386639e, replyNumber=0, likeNumber=56, createdTime=2018-05-22, rootId=0, userName=12498768m15(暂无昵称), userId=34847549422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ce31386639e, moduleTitle=EMA确认AbbVie的MS药物Zinbryta的风险超过益处, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4ce31386639e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Abbvie

2020-05-29

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售

2022-03-16

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

老花眼有救了？AbbVie提交新药上市申请

2021-02-28

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-06-10

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎

2020-06-06

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-02-04

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2019-12-09

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周

2019-09-29

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

AbbVie靶向癌症干细胞的ADC药物Rova-T治疗小细胞肺癌失败，宣布终止研发计划

2019-09-03

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例

2019-08-31

智智灵药 (审核中...)

前往app查看评论内容

#Abbvie#

AbbVie收购Mavupharma，以抓住肿瘤免疫新靶点STING的机遇

2019-07-18

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

2019 ASCO：AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据

2019-06-07

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

2019-06-03

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

欧洲批准AbbVie的白细胞介素23单抗Skyrizi治疗银屑病

2019-05-03

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

即使高管薪酬审查很严厉，AbbVie首席执行官仍拿着2100万美元的巨额奖金

2019-03-14

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利

2019-01-31

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

2019-01-31

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请

2018-12-27

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2018-09-28

12498768m15(暂无昵称) (审核中...)

前往app查看评论内容

#Abbvie#

EMA确认AbbVie的MS药物Zinbryta的风险超过益处

2018-05-22

科室
- - 订阅+
  - 更多科室
工具
服务